Rosiglitazone Maleate

马来酸罗格列酮

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameRosiglitazone Maleate
Drug Alias Name罗格列酮马来酸盐RSG XR罗格列酮Rosiglitazone extendedreleaseRosiglitazonum +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsRejection of renal transplantationCNS Embryonal TumorCognitive Dysfunction +[34] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date1999/05/25
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxo Smith Kline Tianjin Co Ltd
Inactive CompaniesDana-Farber Cancer InstituteRadboud University Medical CenterUniversity Of California San Francisco +[27] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsRejection of renal transplantationCNS Embryonal TumorCognitive Dysfunction +[33] 

Other Information

ATC CodeA10BG02
Related LinksWikipediaDrugBankKEGG